Blueprint Medicines Corporation (BPMC)
Stock Price:
$107.26 USD
1.94 (1.84%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
5.98B |
| Revenue (ttm) |
811.16M |
| Net Income (ttm) |
333.22M |
| Shares Out |
55.73M |
| EPS (ttm) |
6.18 |
| PE Ratio |
17.36 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$107.26 |
| Previous Close |
$105.32 |
| Change ($) |
1.94 |
| Change (%) |
1.84% |
| Day's Open |
105.21 |
| Day's Range |
105.21 - 108.12 |
| Day's Volume |
163,865 |
| 52-Week Range |
43.29 - 108.51 |
More Stats
| Market Cap |
5.98B |
| Enterprise Value |
5.31B |
| Earnings Date (est) |
Mar 5, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
55.73M |
| Float |
54.91M |
| EPS (basic) |
5.77 |
| EPS (diluted) |
6.18 |
| FCF / Share |
6.54 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
5.76% |
| FCF Yield |
6.03% |
| Payout Ratio |
n/a |
| Shares Short |
3.45M |
| Short Ratio |
8.14 |
| Short % of Float |
6.28% |
| Beta |
0.95 |
| PE Ratio |
17.36 |
| Forward PE |
n/a |
| P/FCF Ratio |
16.58 |
| PS Ratio |
7.37 |
| PB Ratio |
4.45 |
| Revenue |
811.16M |
| Operating Income |
325.29M |
| Net Income |
333.22M |
| Free Cash Flow |
360.58M |
| Net Cash |
671.19M |
| Net Cash / Share |
12.04 |
| Gross Margin |
-32.66% |
| Operating Margin |
40.10% |
| Profit Margin |
41.10% |
| FCF Margin |
44.45% |
| ROA |
17.71% |
| ROE |
36.29% |
| ROIC |
49.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (15)
| Buy |
10 |
| Overweight |
1 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$114.93*
(7.15% upside)
Low
81.0
Current: $107.26
High
146.0
Target: 114.93
*Average 12-month price target from 14 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 66.51 | 44.52 | 21.43 | 27.77 | 11.40 | - | - |
| Revenue Growth | 49.39% | 107.79% | -22.85% | 143.61% | - | - | - |
| Gross Profit | 66.51 | 44.52 | 21.43 | 27.77 | 11.40 | - | - |
| Operating Income | -361 | -247 | -151 | -72.58 | -51.64 | -39.73 | -21.00 |
| Net Income | -348 | -237 | -148 | -72.50 | -52.77 | -40.29 | -20.91 |
| Shares Outstanding | 47.83 | 43.87 | 37.79 | 27.49 | 18.24 | 1.42 | 1.02 |
| Earnings Per Share | -7.27 | -5.39 | -3.92 | -2.64 | -3.07 | -32.41 | -23.43 |
| Operating Cash Flow | -278 | -175 | -120 | -24.51 | -31.68 | -35.40 | -19.03 |
| Capital Expenditures | -14.01 | -12.68 | -15.51 | -2.35 | -4.88 | -0.70 | -0.26 |
| Free Cash Flow | -292 | -188 | -135 | -26.87 | -36.56 | -36.10 | -19.28 |
| Cash & Equivalents | 489 | 499 | 678 | 215 | 164 | 47.43 | 2.18 |
| Total Debt | 95.95 | - | 1.52 | 4.07 | 7.34 | 9.04 | 2.86 |
| Net Cash / Debt | 393 | 499 | 676 | 211 | 157 | 38.39 | -0.69 |
| Assets | 708 | 540 | 716 | 283 | 179 | 49.93 | 4.14 |
| Liabilities | 243 | 121 | 91.77 | 69.72 | 34.92 | 129 | 45.59 |
| Book Value | 464 | 419 | 624 | 213 | 144 | -79.38 | -41.45 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Blueprint Medicines Corporation |
| Country |
United States |
| Employees |
420 |
| CEO |
Jeffrey W. Albers |
Stock Information
| Ticker Symbol |
BPMC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BPMC |
| IPO Date |
April 30, 2015 |
Description
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.